Isothiocyanates (ITCs) are natural compounds abundant in cruciferous vegetables. Numerous studies have shown that ITCs exhibit anticancer activity by affecting multiple pathways including apoptosis and oxidative stress, and are expected to be developed into novel anticancer drugs. In our previous studies, we demonstrated that ITCs effectively inhibit the proliferation of
non-small cell lung cancer (NSCLC) cells, also induce apoptosis and autophagy. In the present study, we found that
phenethyl isothiocyanate (
PEITC) had significant synergistic effects with
epidermal growth factor receptor tyrosine kinase inhibitor Gefitinib in NSCLC cell lines NCI-H1299 and SK-MES-1; and the degradation of antiapoptotic factor myeloid cell
leukemia 1 (Mcl-1) caused by
PEITC treatment played key roles in the sensitivity of NSCLC cells to
Gefitinib. We further illustrated that
PEITC regulated the expression of Mcl-1 through
protein kinase RNA-like endoplasmic reticulum
kinase (PERK)-eukaryotic translation
initiation factor 2α-CHOP-Noxa pathway by a posttranscriptional modulation. Pretreatment with endoplasmic reticulum stress (ER stress) inhibitor
tauroursodeoxycholic acid and knockdown of PERK expression attenuated the degradation of Mcl-1 caused by
PEITC. In in vivo study, nude mice bearing NCI-H1299 xenograft were administrated with
PEITC (50 mg/kg, ip) and
Gefitinib (50 mg/kg, ig) for 15 days, the
PEITC-
Gefitinib combination treatment resulted in a significant synergistic reduction in
tumor growth, and significantly induced both ER stress and Mcl-1 degradation in
tumor tissues. In conclusion, we explored the prospect of
PEITC in improving the efficacy of targeted
drug therapy and demonstrated the synergistic effects and underlined mechanisms of
PEITC combined with
Gefitinib in NSCLC cells treatment. This study provided useful information for developing novel
therapy strategies by combination treatment of
PEITC with targeted drugs.